However, it remains unclear how the observed mTOR inhibition due to FLCN loss could lead to tumorigenesis, given that mTOR has been shown to be hyperactivated in tumors of BHD patients and FLCN-deficient mice [37,38]. This evidence concerns the gene FLCN and Birt-Hogg-Dube syndrome.